Edesa Biotech Engages Investors at Global Conferences

Edesa Biotech (EDSA) has released an update.

Edesa Biotech, a clinical-stage biopharmaceutical company, has announced its participation in several investor conferences, including events in Toronto, London, and New York. The company, known for developing therapeutics for immuno-inflammatory diseases, is currently advancing their lead drug candidate, EB05, in a Phase 3 study for ARDS, with plans to initiate a Phase 2 study for pulmonary fibrosis. Additionally, Edesa is exploring treatments for vitiligo and chronic Allergic Contact Dermatitis through its dermatology assets.

For further insights into EDSA stock, check out TipRanks’ Stock Analysis page.